FIELD NOTE
Medtronic Just Paid $700 Million to Sell Someone Else's Robot
Medtronic will distribute a rival soft-tissue robot alongside Hugo in China, Singapore and Europe. Enovis, the same day, bought its robot outright.
Medtronic spent the better part of a decade and an undisclosed fortune building Hugo. On Tuesday, it announced it would put roughly $700 million into Cornerstone Robotics, a Hong Kong company whose Sentire system competes for the same soft-tissue procedures, and distribute that robot alongside Hugo in China, Singapore and Europe.
The structure matters. This is an investment plus distribution rights, not an acquisition. Cornerstone keeps ownership of the platform and its IP. Medtronic gets a second console to put in front of hospitals that, for whatever reason, don’t want its first one.
Sentire is not a science project. It won CE mark in May for general, gynecologic, thoracic and urologic surgery, was approved in China in 2024, and is cleared in Singapore. Cornerstone raised about $200 million last November and operates a 30,000-square-meter manufacturing facility in China. The system has dual-console capability and an immersive console architecture that Medtronic’s own release describes as “a familiar configuration” — industry shorthand for something that looks and feels like da Vinci.
Hugo, by contrast, is less than a year past its first U.S. clearance, in urology, with 510(k)s pending for general surgery and gynecology. It is installed in more than 35 countries, and Medtronic expects total procedures to pass 50,000 by fiscal year-end on roughly 250 installed units.
On the earnings call the same morning, an analyst asked CEO Geoff Martha whether the deal signaled doubt about Hugo. “It’s just the opposite,” Martha said, calling it “a global play” and “one of a number of investments we’re making in soft tissue.” Global robotic penetration, he noted, is still in the single digits, and in emerging markets closer to 1%.
Read those two facts together and the strategy is legible. Medtronic is not hedging Hugo. It is conceding that one platform, priced and configured one way, cannot capture a market this early and this fragmented. Hospitals in Shenzhen and hospitals in Stuttgart are not buying the same robot for the same reasons at the same price. The company’s release says it plainly: “flexibility across clinical settings, procedural needs, and economic models.” That last phrase is the one to underline. Economic models. The technology was never the binding constraint on robotic adoption. The capital cost, the service contract, the per-procedure consumables, the utilization math a CFO has to defend — those were.
The same day, Enovis chose the opposite instrument. The orthopedics company agreed to buy France-based eCential Robotics for €155 million upfront and up to €35 million in milestones. eCential built J&J’s Velys Spine robot. Enovis had already been collaborating with it; now it wants the roughly 50-person team in-house to ship a knee robot in late 2028 and a shoulder robot in 2029. CEO Damien McDonald told investors the rationale was “agility.” The market’s response was a 16.5% share-price drop, mostly on margin dilution.
Two companies, one day, two answers to the same question: when you’re behind in robotics, do you build, buy, or distribute? Enovis, with no robot and a competitive gap its own analysts call its most notable, bought the capability. Medtronic, with a robot and a global ecosystem already in place, bought the option to sell a second one without absorbing the platform risk.
Neither is obviously right. Enovis now owns the engineering but also owns 2027’s margin hit and two launch dates it has to hit. Medtronic keeps its balance sheet lighter but has to manage a sales force selling two competing consoles and explain to every Hugo customer why the other robot exists.
What both deals share is an admission that the era of the single flagship robot is ending before most of the flagships have fully launched. Intuitive built one platform and let the market come to it. Its challengers, arriving into a market where the incumbent already sets the terms, are discovering they may need several.
Medtronic also disclosed a smaller move Tuesday: up to $80 million into Pi-Cardia, a structural heart company, with an option to acquire. Same architecture. Stake first, ownership later, if the numbers hold.
For anyone building a device company: the largest strategics are increasingly structuring their commitments as options, not acquisitions. That changes what “a partnership with Medtronic” means when it shows up in a term sheet.
SPONSORED BY RŌG HEALTH
Most device companies don't fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.